Resultados da busca - Peter Button

A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice por Ian R. Woodcock, George Tachas, Nuket Desem, Peter J. Houweling, Michael Kean, Jaiman Emmanuel, Rachel Kennedy, Kate Carroll, Katy de Valle, Justine Adams, Shireen R. Lamandé, Chantal Coles, Chrystal Tiong, Matthew Burton, Daniella Villano, Peter Button, Jean-Yves Hogrel, Sarah Catling-Seyffer, Monique M. Ryan, Martin B. Delatycki, Eppie M. Yiu

Obter o texto integral

A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice. por Ian R Woodcock, George Tachas, Nuket Desem, Peter J Houweling, Michael Kean, Jaiman Emmanuel, Rachel Kennedy, Kate Carroll, Katy de Valle, Justine Adams, Shireen R Lamandé, Chantal Coles, Chrystal Tiong, Matthew Burton, Daniella Villano, Peter Button, Jean-Yves Hogrel, Sarah Catling-Seyffer, Monique M Ryan, Martin B Delatycki, Eppie M Yiu

Obter o texto integral

Blinatumomab in de novo AYA ALL—Results of the Australasian Leukaemia and Lymphoma Group ALL09 “SUBLIME” study por Matthew Greenwood, Shane Gangatharan, Michael Osborn, Ashley P. Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Jacqueline Rehn, Elyse Page, Susan Heatley, Peter Button, Leesa Rowley, Stephen R. Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla Pozza, David Yeung, Deborah White, the Australasian Leukaemia and Lymphoma Group

Obter o texto integral